Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Inventory: 2012-2025

Historic Inventory for Veracyte (VCYT) over the last 12 years, with Sep 2025 value amounting to $20.3 million.

  • Veracyte's Inventory fell 0.18% to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year decrease of 0.18%. This contributed to the annual value of $21.8 million for FY2024, which is 34.86% up from last year.
  • Veracyte's Inventory amounted to $20.3 million in Q3 2025, which was down 18.76% from $25.0 million recorded in Q2 2025.
  • Over the past 5 years, Veracyte's Inventory peaked at $25.0 million during Q2 2025, and registered a low of $6.3 million during Q1 2021.
  • For the 3-year period, Veracyte's Inventory averaged around $18.7 million, with its median value being $19.3 million (2024).
  • In the last 5 years, Veracyte's Inventory surged by 141.04% in 2021 and then fell by 20.74% in 2023.
  • Over the past 5 years, Veracyte's Inventory (Quarterly) stood at $11.2 million in 2021, then increased by 27.34% to $14.3 million in 2022, then rose by 12.83% to $16.1 million in 2023, then surged by 34.86% to $21.8 million in 2024, then declined by 0.18% to $20.3 million in 2025.
  • Its Inventory was $20.3 million in Q3 2025, compared to $25.0 million in Q2 2025 and $24.3 million in Q1 2025.